Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in ...
Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with ...
An international team of researchers has produced complete, gap-free genome sequences for six peanut varieties, providing a ...
Morning Overview on MSN
Study ties hidden DNA region to frailty and aging risk
Frailty can creep up quietly. One year a person is carrying groceries without thinking about it; a few years later, a stumble ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results